Insider Trading (Wed 6/8/22)

Notable purchases -- CEO and Director add to KPLT; notable sales -- Director active in NCNO

Buyers:

• CBAY CEO bought 51,301 shares at $1.95 worth ~ $100K.
  
• CGEM CEO bought 8,090 shares at $12.34 - $12.45 worth ~ $100K.
  
• COMM CFO bought 17,887 shares at $8.09 - $8.11 worth ~ $140K.
  
• HRT Director bought 29,991 shares at $14.85 - $14.99 worth ~ $450K.
  
• KIND Director bought 5,837,072 shares at $3.03 - $3.62 worth ~ $19.4 mln.
  
• KPLT CEO and Director bought 278,472 shares at $1.38 - $1.57 worth ~ $430K.
  
• LGF.B Director bought 58,687 Class B common shares at $9.12 - $9.81 worth ~ $560K.
  
• OPK CEO & Chairman bought 100,000 shares at $2.77 - $2.82 worth ~ $280K.
  
• PDLB CFO and Executive Chairman bought 12,000 shares at $9.23 - $9.25 worth ~ $110K.

Sellers:

• BMY EVP, General Counsel sold 65,000 shares at $74.87 - $74.91 worth ~ $4.9 mln.
  
• FEAM 10% Owner sold 500,000 shares at $25.00 - $25.01 worth ~ $12.5 mln.
  
• FLYW Director sold 1,240,490 shares at $19.60 worth ~ $24.3 mln.
  
• GPN Senior EVP & General Counsel sold 16,252 shares at $129.95 - $130.29 worth ~ $2.1 mln.
  
• MDRX Director sold 140,450 shares at $17.30 - $17.40 worth ~ $2.4 mln.
  
• NCNO Director sold 100,000 shares at $35.00 - $37.14 worth ~ $3.6 mln.
  
• PCOR Director sold 54,378 shares at $46.14 - $47.42 worth ~ $2.5 mln.
  
• RPTX Director sold 750,000 shares at $12.25 - $12.50 worth ~ $9.2 mln.

-=Allscripts Healthcare (MDRX) reported earnings on Thur 15 Feb 2018 (a/h)

Allscripts Healthcare reports EPS in-line, beats on revs; guides FY18 EPS in-line, revs above consensus; sells OneContent to Hyland Software 

• Reports Q4 (Dec) earnings of $0.18 per share, excluding non-recurring items, in-linewith the Capital IQ Consensus of $0.18; revenues rose 27.5% year/year to $547 mln vs the $524.05 mln Capital IQ Consensus.
• Co issues guidance for FY18, sees EPS of $0.72-0.82, excluding non-recurring items, vs. $0.79 Capital IQ Consensus Estimate; sees FY18 revs of $2.15-2.25 bln vs. $2.15 bln Capital IQ Consensus Estimate. 
• Co will sell its OneContent business to Hyland Software, Inc., a leading provider of content services solutions to the healthcare industry and beyond. The deal is expected to close in the second quarter once customary closing conditions are satisfied. Allscripts acquired the OneContent business in late 2017 through the acquisition of McKesson's EIS portfolio. Upon transaction close, the OneContent client base and associates will transition to Hyland. The two companies will operate independently until the deal closes. Bookings were $314 million in the fourth quarter of 2017. 
• Today, we amended the Allscripts Credit Agreement, providing for an increase in available liquidity and tenor as well as lower interest rates. The amendment provides a $400 million term loan and a $900 million revolving facility. This represents an increase in borrowing capacity of $500 million and the maturity date was extended to 2023. 
• Allscripts announced it has completed the acquisition of Practice Fusion, a cloud-based electronic health record aimed primarily at small, independent physician practices. This transaction gives Allscripts the largest US market share in outpatient settings and makes Allscripts the largest owner of "actionable" clinical data sets. Approximately 30,000 ambulatory sites, serving 5 million patients each month, currently use Practice Fusion EHR, practice management, e-prescribing, lab and patient portal technology.

Allscripts Healthcare Solutions (MDRX) reported earnings on Thur 3 Aug 2017 (a/h)

** charts after earnings **

CHICAGO (AP) _ Allscripts Healthcare Solutions Inc. (MDRX) on Thursday reported a loss of $153.7 million in its second quarter.

On a per-share basis, the Chicago-based company said it had a loss of 85 cents. Earnings, adjusted for one-time gains and costs, came to 15 cents per share.

The results met Wall Street expectations. The average estimate of 15 analysts surveyed by Zacks Investment Research was also for earnings of 15 cents per share.

The electronic health records company posted revenue of $426.1 million in the period. Its adjusted revenue was $427.7 million, which topped Street forecasts. Ten analysts surveyed by Zacks expected $424.2 million.

AllScripts expects full-year revenue in the range of $1.71 billion to $1.74 billion.

AllScripts shares have climbed 14 percent since the beginning of the year. In the final minutes of trading on Thursday, shares hit $11.67, a decrease of 18 percent in the last 12 months.